Cello Health expands with Defined Health acquisition

Cello Health has strengthened its US operations with the acquisition of business development specialist Defined Health.

The agency brings a particular focus in biotech strategy solutions to Cello Health, adding to the group's current offering in global marketing research and customer insight, strategic consulting, and evidence and engagement services.

Defined Health will work closely with its new parent company in early asset development and commercialisation, with a particular focus on defining value for early-stage compounds. The firm is also set to boost Cello Health's US capabilities in communications and insight, as well as areas such as market access.

Stephen Highley, chairman of Cello Health, said: “Defined Health has achieved a strong reputation by working closely with clients to build and strengthen biotech development-stage assets.

“Understanding the commercial opportunity and applicability of early stage assets is of fundamental importance to our clients and Defined Health positions Cello Health to be able to deliver to this requirement."

Defined Health also brings its thought leadership programme to the healthcare group, which includes its annual Cancer Progress conference - now in its 27th year - and the Therapeutic Insight conferences that cover an array of therapy areas.

Defined Health's president and founder Ed Saltzman, said: “Cello Health's core capabilities both augment and powerfully synergize with our own and will serve to increase the value we can offer our clients through the full span of the development process from early development to commercial launch.

“We are extremely excited to be part of Cello Health.”